This company is no longer active
GMTX Stock Overview
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD).
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Gemini Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.35 |
| 52 Week High | US$3.10 |
| 52 Week Low | US$1.16 |
| Beta | -0.12 |
| 11 Month Change | -21.51% |
| 3 Month Change | -17.68% |
| 1 Year Change | -53.61% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -86.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| GMTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -12.9% | 4.3% | 5.1% |
| 1Y | -53.6% | 29.2% | 37.7% |
Return vs Industry: GMTX underperformed the US Biotechs industry which returned -10.7% over the past year.
Return vs Market: GMTX underperformed the US Market which returned -23.1% over the past year.
Price Volatility
| GMTX volatility | |
|---|---|
| GMTX Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: GMTX's share price has been volatile over the past 3 months.
Volatility Over Time: GMTX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 24 | Georges Gemayel | www.geminitherapeutics.com |
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases.
Gemini Therapeutics, Inc. Fundamentals Summary
| GMTX fundamental statistics | |
|---|---|
| Market cap | US$58.49m |
| Earnings (TTM) | -US$43.42m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.3x
P/E RatioIs GMTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GMTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$43.42m |
| Earnings | -US$43.42m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.00 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did GMTX perform over the long term?
See historical performance and comparison